Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Neurol Neurosurg Psychiatry. 2022 May;93(5):491-498. doi: 10.1136/jnnp-2021-327512. Epub 2022 Feb 25.
Up to 40% of patients with idiopathic generalised epilepsy (IGE) are drug resistant and potentially could benefit from intracranial neuromodulation of the seizure circuit. We present outcomes following 2 years of thalamic-responsive neurostimulation for IGE.
Four patients with pharmacoresistant epilepsy underwent RNS System implantation in the bilateral centromedian (CM) nucleus region. Electrophysiological data were extracted from the clinical patient data management system and analysed using a specialised platform (BRAINStim). Postoperative visualisation of electrode locations was performed using Lead-DBS. Seizure outcomes were reported using the Engel scale.
Patients experienced a 75%-99% reduction in seizure frequency with decreased seizure duration and severity (Engel class IB, IC, IIA and IIIA), as well as significant improvements in quality of life. Outcomes were durable through at least 2 years of therapy. Detection accuracy for all patients overall decreased over successive programming epochs from a mean of 96.5% to 88.3%. Most electrodes used to deliver stimulation were located in the CM (7/10) followed by the posterior dorsal ventral lateral (2/2), posterior ventral posterior lateral (3/4) and posterior ventral ventral lateral (2/3). In all patients, stimulation varied from 0.2 to 2.0 mA and amplitude only increased over successive epochs. The raw percentage of intracranial electroencephalography recordings with stimulations delivered to electrographic seizures was 24.8%, 1.2%, 7.6% and 8.8%.
Closed-loop stimulation of the CM region may provide significant improvement in seizure control and quality of life for patients with drug-resistant IGE. Optimal detection and stimulation locations and parameters remain an active area of investigation for accelerating and fine-tuning clinical responses.
高达 40%的特发性全面性癫痫(IGE)患者对药物治疗无反应,可能受益于颅内癫痫回路的神经调节。我们报告了 2 年丘脑反应性神经刺激治疗 IGE 的结果。
4 例药物难治性癫痫患者在双侧中央中核(CM)核区植入 RNS 系统。从临床患者数据管理系统中提取电生理数据,并使用专门的平台(BRAINStim)进行分析。使用 Lead-DBS 进行术后电极位置可视化。使用 Engel 量表报告癫痫发作结果。
患者的癫痫发作频率降低了 75%-99%,癫痫发作持续时间和严重程度降低(Engel 分级 IB、IC、IIA 和 IIIA),生活质量也显著提高。至少 2 年的治疗效果持久。所有患者的总体检测准确性随着连续编程阶段的推移从平均 96.5%下降到 88.3%。用于提供刺激的大多数电极位于 CM(7/10),其次是后背侧腹侧外侧(2/2)、后腹侧后外侧(3/4)和后腹侧腹侧外侧(2/3)。在所有患者中,刺激幅度在 0.2 到 2.0 mA 之间变化,幅度仅在连续阶段增加。有刺激的颅内脑电图记录的原始百分比为 24.8%、1.2%、7.6%和 8.8%。
CM 区的闭环刺激可能为药物难治性 IGE 患者提供显著的癫痫控制和生活质量改善。最佳检测和刺激位置以及参数仍然是一个活跃的研究领域,旨在加速和微调临床反应。